Re-Evaluation of the Efficacy of Azacitidine (AZA) In Patients From the AZA-001 Study with Higher-Risk Myelodysplastic Syndromes (MDS) Classified by WHO Criteria and WPSS Risk.

被引：0
|
作者：
Gattermann, Norbert [1 ]
Sanz, Guillermo F. [2 ]
Giagounidis, Aristoteles [3 ]
Seymour, John F. [4 ]
Fenaux, Pierre [5 ]
Santini, Valeria [6 ]
Mufti, Ghulam J. [7 ]
Muus, Petra [8 ]
Ramos, Fernando [9 ,10 ]
Lucy, Lela M. [11 ]
Beach, C. L. [11 ]
Silverman, Lewis R. [12 ]
机构：
[1] Univ Dusseldorf, Dept Hematol Oncol, Dusseldorf, Germany
[2] Hosp Univ La Fe, Dept Hematol, Valencia, Spain
[3] St Johannes Hosp, Med Klin 2, Duisburg, Germany
[4] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[5] Univ Paris 13, Hop Avicenne, Serv Hematol Clin, Bobigny, France
[6] UF Ematol AOU Careggi, Florence, Italy
[7] Kings Coll Hosp London, London, England
[8] Radboud Univ Nijmegen, Med Ctr, Dept Hematol, NL-6525 ED Nijmegen, Netherlands
[9] Hosp Leon, Leon, Spain
[10] IBIOMED, Leon, Spain
[11] Celgene Corp, Overland Pk, KS USA
[12] Mt Sinai Sch Med, Div Hematol Oncol, New York, NY USA
来源：
BLOOD | 2010年 / 116卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1643 / 1644
页数：2
相关论文
共 50 条
  • [31] PHASE 3 VERONA STUDY ASSESSING THE SAFETY AND EFFICACY OF VENETOCLAX WITH AZACITIDINE IN PATIENTS WITH NEWLY DIAGNOSED HIGHER-RISK MYELODYSPLASTIC SYNDROMES
    Zeidan, A. M.
    Garcia, J.
    Fenaux, P.
    Platzbecker, U.
    Miyazaki, Y.
    Xiao, Z.
    Zhou, Y.
    Naqvi, K.
    Kye, S.
    Manero, G. Garcia
    LEUKEMIA RESEARCH, 2021, 108 : S47 - S47
  • [32] A Prognostic Score for Overall Survival (OS) with Azacitidine (AZA) In Higher Risk MDS Based on 282 Patients (pts), and Validated In 175 Pts From the AZA 001 Trial.
    Itzykson, Raphael
    Thepot, Sylvain
    Quesnel, Bruno
    Dreyfus, Francois
    Beyne-Rauzy, Odile
    Turlure, Pascal
    Recher, Christian
    Dartigeas, Caroline
    Vey, Norbert
    Legros, Laurence
    Delaunay, Jacques
    Salanoubat, Celia
    Visanica, Sorin
    Stamatoullas, Aspasia
    Isnard, Francoise
    Marfaing-Koka, Anne
    De Botton, Stephane
    Chelgoum, Youcef
    Taksin, Anne-Laure
    Plantier, Isabelle
    Ame, Shanti
    Boehrer, Simone
    Gardin, Claude
    Beach, C. L.
    Ades, Lionel
    Fenaux, Pierre
    BLOOD, 2010, 116 (21) : 1628 - 1629
  • [33] A Phase II Study Of The Combination Of Azacitidine and Lenalidomide In Patients (pts) With Higher Risk Myelodysplastic Syndromes (MDS)
    Garcia-Manero, Guillermo
    Kadia, Tapan M.
    Daver, Naval
    Jabbour, Elias
    Jain, Nitin
    Cortes, Jorge E.
    Estrov, Zeev
    Borthakur, Gautam
    Dong, Xiao Q.
    Kumar, Veeral J.
    Kantarjian, Hagop M.
    BLOOD, 2013, 122 (21)
  • [34] Patient outcome measures during prolonged survival in patients (Pts) with high-risk myelodysplastic syndromes (MDS) treated with azacitidine (AZA)
    Santini, V.
    Fenaux, P.
    Mufti, G. J.
    Hellstroem-Lindberg, E.
    List, A. F.
    Silverman, L. R.
    Seymour, J. F.
    Backstrom, J.
    McKenzie, D.
    Beach, C. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [35] Preliminary Results of a Phase 2 Study of IMM01 Combined with Azacitidine (AZA) As the First-Line Treatment in Adult Patients with Higher Risk Myelodysplastic Syndromes (MDS)
    Yang, Wei
    Gao, Sujun
    Yan, Xiaojing
    Guo, Rong
    Han, Lijie
    Li, Fei
    Wang, Yafei
    Li, Junmin
    Chang, Chunkang
    Yang, Haiping
    Hu, Ronghua
    Tong, Hongyan
    Zhao, Xingli
    Li, Qiubai
    Zhang, Jingdong
    Du, Xin
    Tu, Sanfang
    Zhang, Cheng
    Lin, Congmeng
    Du, Xin
    Li, Zhenling
    Liu, Ligen
    Li, Zhenyu
    Dong, Zheng
    Yang, Yixuan
    Lu, Qiying
    Tian, Wenzhi
    Xiao, Zhijian
    BLOOD, 2023, 142
  • [36] Magrolimab plus Azacitidine Versus Azacitidine plus Placebo in Untreated Higher-Risk (HR) Myelodysplastic Syndromes (MDS): The Phase 3, Randomized, ENHANCE Study
    Garcia-Manero, Guillermo
    Daver, Naval
    Xu, Jin
    Chao, Mark
    Chung, Trisha
    Tan, Anderson
    Wang, Yan
    Wei, Andrew
    Vyas, Paresh
    Sallman, David
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S343 - S344
  • [37] Phase 3 study of first line pevonedistat (PEV) plus azacitidine (AZA) versus single-agent AZA in patients with higher-risk myelodysplastic syndromes (HR MDS), chronic myelomonocytic leukemia (CMML) or low-blast acute myelogenous leukemia (AML).
    Sekeres, Mikkael A.
    Fram, Robert J.
    Hua, Zhaowei
    Ades, Lionel
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [38] CC-486 (ORAL AZACITIDINE) IN PATIENTS WITH INTERNATIONAL PROGNOSTIC SCORING SYSTEM (IPSS)-DEFINED HIGHER-RISK MYELODYSPLASTIC SYNDROMES (MDS)
    Garcia-Manero, G.
    Savona, M. R.
    Gore, S. D.
    Cogle, C. R.
    Conkling, P.
    Hetzer, J.
    Dong, Q.
    Ukrainskyj, S. M.
    Skikne, B. S.
    LEUKEMIA RESEARCH, 2015, 39 : S50 - S51
  • [39] Glasdegib in combination with azacitidine (AZA) in patients (pts) with untreated higher-risk myelodysplastic syndromes (MDS), acute myeloid leukemia (AML) and chronic myelomonocytic leukemia (CMML): Effects on marrow recovery and transfusion independence.
    Zeidan, Amer Methqal
    Schuster, Michael
    Joris, Magalie
    Krauter, Jurgen
    Maertens, Johan
    Gyan, Emmanuel
    Kovacsovics, Tibor
    Verma, Amit
    Vyas, Paresh
    Wang, Eunice S.
    Ma, Wendy
    Zeremski, Mirjana
    Kudla, Art
    Chan, Geoffrey
    Sekeres, Mikkael A.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [40] Health-related quality of life (HRQoL) in patients with untreated higher-risk myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), and chronic myelomonocytic leukemia (CMML) receiving glasdegib plus azacitidine (AZA).
    Wang, Eunice S.
    Bell, Timothy
    Zeidan, Amer Methqal
    Bhattacharyya, Helen
    Kudla, Art
    Chan, Geoffrey
    Sekeres, Mikkael A.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345